CorMedix Inc. Common Stock (CRMD)

About CRMD

CorMedix Inc., a biopharmaceutical company, focuses on developing and commercializing therapeutic products for life-threatening diseases and conditions in the United States. Its lead product candidate is DefenCath, an antimicrobial catheter lock solution to reduce the incidence of catheter-related bloodstream infections in adult patients with kidney failure. CorMedix Inc. was formerly known as Picton Holding Company,…

Sector

Health Care

Industry

Biotechnology: Pharmaceutical Preparations

Employees

191

Website

cormedix.com/

Fundamentals

1-day range

$7.4$7.59

Market cap

$589.17M

P/E (trailing)

3.53

P/E (forward)

21.26

EPS (trailing)

$2.10

Dividend yield

—

Beta

1.41

Avg. volume

1.29M

Dividend pay date

March 26, 2019

Forecasts

5 analyst ratings

CorMedix Inc. Common Stock Competitors

Chosen by industry and closest market cap.

• CRMD

  CorMedix Inc. Common Stock

  $8.31

  ▼ 0.06%
  Market cap $589.17MP/E 3.53
  $6.13$14.96
• MPLT

  MapLight Therapeutics Inc. Common Stock

  $12.64

  ▲ 0.80%
  Market cap $602.19MP/E —
  $9.1$40.43
• CBIO

  Crescent Biopharma Inc. Common Stock

  $17.74

  ▼ 0.14%
  Market cap $610.27MP/E —
  $8.72$27.41
• ARVN

  Arvinas Inc. Common Stock

  $9.16

  ▼ 0.87%
  Market cap $567.55MP/E 62.96
  $6.97$14.51
• SGMT

  Sagimet Biosciences Inc. Series A Common Stock

  $10.55

  ▼ 1.86%
  Market cap $539.71MP/E —
  $4.5$11.15
• NGNE

  Neurogene Inc. Common Stock

  $36.38

  ▼ 3.91%
  Market cap $680.52MP/E —
  $15.93$43.66
• OVID

  Ovid Therapeutics Inc. Common Stock

  $2.81

  ▼ 4.10%
  Market cap $494.60MP/E —
  $1.12$3.11

P/E shows — for peers not currently carrying a live signal of their own.

Latest news

• CorMedix: Durable Commercial Base, But 2027 Is The Real Test
  SeekingAlpha · 8/18/2026
• CRMD Stock Up as Q2 Earnings & Sales Beat on DefenCath, Melinta Gains
  Yahoo · 8/14/2026
• RBC Capital Maintains Outperform on Cormedix, Raises Price Target to $14
  Benzinga · 8/14/2026
• CorMedix Inc. Q2 2026 Earnings Call Summary
  Yahoo · 8/14/2026
• Cormedix Inc (CRMD) (Q2 2026) Earnings Call Highlights: Record Revenue and Raised EBITDA ...
  Yahoo · 8/13/2026
• CorMedix Q2 Earnings Call Highlights
  Yahoo · 8/13/2026
• CorMedix CEO Expects Supplemental Filing For Fungal Disease Treatment By Q3 – CRMD Stock Sees Best Day In Nearly 10 Months After Earnings Beat
  Yahoo · 8/13/2026
• There are notable gap-ups and gap-downs in today's session.
  ChartMill · 8/13/2026

Institutional Ownership

March 31, 2026

Total shares held

42.58M

Total value held

$285.91M

Institutional holders

184